[Double-blind study of the efficacy of an antiserotoninergic drug, pizotifen, in Duchenne's muscular dystrophy].
In 40 patients presenting with Duchenne muscular dystrophy, a double blind therapeutic trial of 18 months was undertaken in order to appreciate the efficacy of pizotifen, an anti-serotoninergic drug. Quarterly evaluations were performed. Each of them included muscular testing on 31 pairs of muscles, timed tests, dynamometric study of the thumb-forefinger grip, functional testing, respiratory function tests, muscular enzyme determinations, parents' subjective estimation and search for side-effects. With respect to the evolution of Duchenne muscular dystrophy, this study did not show significant differences between pizotifen at a dose of 1.5 mg/day and placebo, except for a parents' preference for the drug.
D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000235:genetics; D010918:Pizotyline / Q000494:pharmacology / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013876:Thiophenes / Q000627:therapeutic use*
D013876:Thiophenes; D010918:Pizotyline
Etude en double aveugle de l'efficacité d'un antisérotoninergique, le pizotifène, dans la myopathie de Duchenne de Boulogne.